Clinical trial
Safety and Activity of Rituximab(HLX01) in Combination With Pegylated Interferon α-2b in Patients With Newly Diagnosed Advanced Indolent B-cell Lymphoma: a Single-arm, Multicenter, Phase 2 Study
NCT04246359 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Activity of Rituximab(HLX01) in Combination With Pegylated Interferon α-2b in Patients With Newly Diagnosed Advanced Indolent B-cell Lymphoma: a Single-arm, Multicenter, Phase 2 Study
- Lead sponsor
- Huiqiang Huang
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 15, 2020
- Completion date
- January 16, 2023
- Enrollment
- 52 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.